BHV-0223 + Placebo

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Social Anxiety Disorder

Conditions

Social Anxiety Disorder, Performance Anxiety

Trial Timeline

Jan 1, 2017 → Jan 29, 2021

NCT ID

NCT03017508

About BHV-0223 + Placebo

BHV-0223 + Placebo is a phase 2/3 stage product being developed by Biohaven for Social Anxiety Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03017508. Target conditions include Social Anxiety Disorder, Performance Anxiety.

What happened to similar drugs?

7 of 16 similar drugs in Social Anxiety Disorder were approved

Approved (7) Terminated (4) Active (6)

✅Cariprazine + PlaceboAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅quetiapineAstraZenecaApproved

✅Pristiq + PlaceboPfizerApproved

✅Sertraline + PlaceboPfizerApproved

✅NefazodoneBristol Myers SquibbApproved

✅EscitalopramLundbeckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03017508	Phase 2/3	Completed	Jan 1, 2017	Jan 29, 2021	Social Anxiety Disorder

Competing Products

20 competing products in Social Anxiety Disorder

See all competitors

Product	Company	Stage	Hype Score
LY686017 + paroxetine + placebo	Eli Lilly	Phase 2	35
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Cariprazine + Placebo	AbbVie	Approved	43
Quetiapine	AstraZeneca	Approved	43
quetiapine	AstraZeneca	Phase 3	32
quetiapine	AstraZeneca	Phase 2/3	38
Seroquel + Sugar Pill	AstraZeneca	Phase 3	40
quetiapine	AstraZeneca	Approved	43
Pristiq + Placebo	Pfizer	Approved	43
Venlafaxine ER	Pfizer	Phase 3	40
Ziprasidone + Sertraline	Pfizer	Phase 2	35
Sertraline + Placebo	Pfizer	Approved	35
Nefazodone	Bristol Myers Squibb	Approved	43
Escitalopram	Lundbeck	Approved	40
Cipralex + Placebo	Lundbeck	Phase 2	32
VQW-765 + Placebo	Vanda Pharmaceuticals	Phase 3	37
PH94B	Vistagen Therapeutics	Phase 3	22
Fasedienol Nasal Spray - Placebo Nasal Spray + Fasedienol Nasal Spray - Fasedienol Nasal Spray + Placebo Nasal Spray - Placebo Nasal Spray	Vistagen Therapeutics	Phase 2	32
PH94B Nasal Spray + Placebo Nasal Spray	Vistagen Therapeutics	Phase 3	22